307 related articles for article (PubMed ID: 20028955)
1. Characterizing hospitalizations of end-stage renal disease patients on dialysis and inpatient utilization of erythropoiesis-stimulating agent therapy.
Brophy DF; Daniel G; Gitlin M; Mayne TJ
Ann Pharmacother; 2010 Jan; 44(1):43-9. PubMed ID: 20028955
[TBL] [Abstract][Full Text] [Related]
2. Effect of erythropoiesis-stimulating agents on healthcare utilization, costs, and outcomes in chronic kidney disease.
Maddux FW; Shetty S; del Aguila MA; Nelson MA; Murray BM
Ann Pharmacother; 2007 Nov; 41(11):1761-9. PubMed ID: 17895328
[TBL] [Abstract][Full Text] [Related]
3. Optimizing anemia management in hospitalized patients with end-stage renal disease.
Heung M; Mueller BA; Segal JH
Ann Pharmacother; 2009 Feb; 43(2):276-82. PubMed ID: 19141655
[TBL] [Abstract][Full Text] [Related]
4. Factors affecting survival in advanced chronic kidney disease patients who choose not to receive dialysis.
Wong CF; McCarthy M; Howse ML; Williams PS
Ren Fail; 2007; 29(6):653-9. PubMed ID: 17763158
[TBL] [Abstract][Full Text] [Related]
5. Impact of elevated C-reactive protein levels on erythropoiesis- stimulating agent (ESA) dose and responsiveness in hemodialysis patients.
Bradbury BD; Critchlow CW; Weir MR; Stewart R; Krishnan M; Hakim RH
Nephrol Dial Transplant; 2009 Mar; 24(3):919-25. PubMed ID: 18840893
[TBL] [Abstract][Full Text] [Related]
6. Costs of managing anemia with erythropoiesis-stimulating agents during hemodialysis: a time and motion study.
Schiller B; Doss S; DE Cock E; Del Aguila MA; Nissenson AR
Hemodial Int; 2008 Oct; 12(4):441-9. PubMed ID: 19090867
[TBL] [Abstract][Full Text] [Related]
7. Chronic dialysis-associated anaemia in end-stage renal disease: analysis of management in two French centres.
Perrinet M; Décaudin B; Champs BB; Heran I; Urbina MA; Lemaitre V; Azar R; Odou P
J Clin Pharm Ther; 2010 Aug; 35(4):395-400. PubMed ID: 20831542
[TBL] [Abstract][Full Text] [Related]
8. Predictors of ESA use in the non-dialysis chronic kidney disease population with anemia.
Collins AJ; Guo H; Gilbertson DT; Bradbury BD
Nephron Clin Pract; 2009; 111(2):c141-8. PubMed ID: 19147996
[TBL] [Abstract][Full Text] [Related]
9. Clinical and economic outcomes of Staphylococcus aureus septicemia in ESRD patients receiving hemodialysis.
Nissenson AR; Dylan ML; Griffiths RI; Yu HT; Dean BB; Danese MD; Dubois RW
Am J Kidney Dis; 2005 Aug; 46(2):301-8. PubMed ID: 16112049
[TBL] [Abstract][Full Text] [Related]
10. Duration of end-stage renal disease and kidney transplant outcome.
Goldfarb-Rumyantzev A; Hurdle JF; Scandling J; Wang Z; Baird B; Barenbaum L; Cheung AK
Nephrol Dial Transplant; 2005 Jan; 20(1):167-75. PubMed ID: 15546892
[TBL] [Abstract][Full Text] [Related]
11. Initiation of anaemia management in patients with chronic kidney disease not on dialysis in the Veterans Health Administration.
Lawler EV; Gagnon DR; Fink J; Seliger S; Fonda J; Do TP; Gaziano JM; Bradbury BD
Nephrol Dial Transplant; 2010 Jul; 25(7):2237-44. PubMed ID: 20083469
[TBL] [Abstract][Full Text] [Related]
12. Physician-diagnosed depression as a correlate of hospitalizations in patients receiving long-term hemodialysis.
Hedayati SS; Grambow SC; Szczech LA; Stechuchak KM; Allen AS; Bosworth HB
Am J Kidney Dis; 2005 Oct; 46(4):642-9. PubMed ID: 16183419
[TBL] [Abstract][Full Text] [Related]
13. No associations between prolactin concentrations and response to erythropoiesis-stimulating agents in hemodialysis patients.
Riegersperger M; van Houte M; Födinger M; Wojcik J; Hörl WH; Winkelmayer WC; Sunder-Plassmann G
Am J Nephrol; 2007; 27(4):390-6. PubMed ID: 17587788
[TBL] [Abstract][Full Text] [Related]
14. Comparative Effectiveness of Iron and Erythropoiesis-Stimulating Agent Dosing on Health-Related Quality of Life in Patients Receiving Hemodialysis.
Freburger JK; Ellis AR; Wang L; Butler AM; Kshirsagar AV; Winkelmayer WC; Brookhart MA
Am J Kidney Dis; 2016 Feb; 67(2):271-82. PubMed ID: 26508682
[TBL] [Abstract][Full Text] [Related]
15. When payment systems collide: the effect of hospitalization on anemia in renal dialysis patients.
Turenne MN; Hirth RA; Messana JM; Turner JS; Sleeman KK; Wheeler JR
Med Care; 2010 Apr; 48(4):296-305. PubMed ID: 20195175
[TBL] [Abstract][Full Text] [Related]
16. Biosimilar epoetin zeta in nephrology - a single-dialysis center experience.
Lonnemann G; Wrenger E
Clin Nephrol; 2011 Jan; 75(1):59-62. PubMed ID: 21176751
[TBL] [Abstract][Full Text] [Related]
17. Effect of parathyroidectomy on anemia and erythropoietin dosing in end-stage renal disease patients with hyperparathyroidism.
Trunzo JA; McHenry CR; Schulak JA; Wilhelm SM
Surgery; 2008 Dec; 144(6):915-8; discussion 919. PubMed ID: 19040997
[TBL] [Abstract][Full Text] [Related]
18. Hyporesponsiveness to erythropoiesis-stimulating agents and renal survival in non-dialysis CKD patients.
Minutolo R; Conte G; Cianciaruso B; Bellizzi V; Camocardi A; De Paola L; De Nicola L
Nephrol Dial Transplant; 2012 Jul; 27(7):2880-6. PubMed ID: 22319218
[TBL] [Abstract][Full Text] [Related]
19. High frequency of linezolid-associated thrombocytopenia and anemia among patients with end-stage renal disease.
Wu VC; Wang YT; Wang CY; Tsai IJ; Wu KD; Hwang JJ; Hsueh PR
Clin Infect Dis; 2006 Jan; 42(1):66-72. PubMed ID: 16323094
[TBL] [Abstract][Full Text] [Related]
20. Drug utilization and cost for erythropoiesis-stimulating agents in a long-term care resident population with chronic kidney disease.
Lafeuille MH; Bailey RA; Vekeman F; Kilpatrick BS; Senbetta M; Piech CT; Lefebvre P
Consult Pharm; 2010 Aug; 25(8):493-500. PubMed ID: 20736158
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]